GlassScriptPhysician profile
Kashif A Shaikh
NPI 1770901894
$7,311.47
in general payments reported to CMS, 2019-2025
24 companies · $741 in 2025
The $741 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $202 · 2023: $2,428 · 2024: $3,940 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,443 · Travel and Lodging: $2,166 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,442.58 |
| Travel and Lodging | $2,166.41 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $2,995.70 | 2022-2025 | Ffrct |
| Canon Medical Systems USA, INC. | $1,648.88 | 2023 | Toshiba Scanner |
| Abbott Laboratories | $1,002.62 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $445.34 | 2022-2025 | Lifevest |
| Boston Scientific Corporation | $219.72 | 2022-2025 | Watchman Flx |
| Atricure, INC. | $193.33 | 2023-2024 | |
| Pfizer INC. | $156.72 | 2022-2025 | |
| Cleerly, INC. | $110.57 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Ge Healthcare | $66.68 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $66.18 | 2023 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $56.28 | 2024 | |
| Amgen INC. | $53.52 | 2023-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals International, Plc | $41.03 | 2024 | Arcalyst |
| Canon Medical Informatics, INC. | $40.81 | 2024 | Vitrea Advanced Visualization |
| Actelion Pharmaceuticals US, INC. | $40.25 | 2024-2025 | Uptravi, Opsumit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $35.23 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $28.79 | 2023-2024 | Eliquis |
| Scpharmaceuticals INC. | $19.51 | 2025 | |
| Philips North America LLC | $16.72 | 2024 | (Ck4) Mcot |
| Genzyme Corporation | $16.69 | 2025 | |
| Edwards Lifesciences Corporation | $16.54 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.23 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $14.78 | 2023 | |
| Inogen, INC. | $10.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashif Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.